GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SELLAS Life Sciences Group Inc (FRA:RXK3) » Definitions » Cyclically Adjusted Price-to-FCF

SELLAS Life Sciences Group (FRA:RXK3) Cyclically Adjusted Price-to-FCF : (As of Jun. 05, 2025)


View and export this data going back to 2008. Start your Free Trial

What is SELLAS Life Sciences Group Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


SELLAS Life Sciences Group Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for SELLAS Life Sciences Group's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SELLAS Life Sciences Group Cyclically Adjusted Price-to-FCF Chart

SELLAS Life Sciences Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

SELLAS Life Sciences Group Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of SELLAS Life Sciences Group's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, SELLAS Life Sciences Group's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SELLAS Life Sciences Group's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SELLAS Life Sciences Group's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where SELLAS Life Sciences Group's Cyclically Adjusted Price-to-FCF falls into.


;
;

SELLAS Life Sciences Group Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

SELLAS Life Sciences Group's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, SELLAS Life Sciences Group's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.096/134.9266*134.9266
=-0.096

Current CPI (Mar. 2025) = 134.9266.

SELLAS Life Sciences Group Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -2,116.200 100.684 -2,835.922
201509 -1,694.200 100.392 -2,277.012
201512 -2,819.400 99.792 -3,812.034
201603 -1,978.833 100.470 -2,657.471
201606 -1,704.500 101.688 -2,261.645
201609 -1,553.857 101.861 -2,058.262
201612 2,376.200 101.863 3,147.497
201703 -142.240 102.862 -186.579
201706 -104.385 103.349 -136.279
201709 -625.577 104.136 -810.549
201712 112.043 104.011 145.346
201803 -36.824 105.290 -47.189
201806 -39.941 106.317 -50.689
201809 -34.388 106.507 -43.564
201812 -9.079 105.998 -11.557
201903 -9.881 107.251 -12.431
201906 -6.379 108.070 -7.964
201909 -0.810 108.329 -1.009
201912 -0.740 108.420 -0.921
202003 -0.970 108.902 -1.202
202006 -0.447 108.767 -0.555
202009 -0.366 109.815 -0.450
202012 0.271 109.897 0.333
202103 -0.580 111.754 -0.700
202106 -0.266 114.631 -0.313
202109 -0.315 115.734 -0.367
202112 -0.277 117.630 -0.318
202203 -0.408 121.301 -0.454
202206 -0.269 125.017 -0.290
202209 -0.282 125.227 -0.304
202212 -0.234 125.222 -0.252
202303 -0.481 127.348 -0.510
202306 -0.246 128.729 -0.258
202309 -0.228 129.860 -0.237
202312 -0.144 129.419 -0.150
202403 -0.221 131.776 -0.226
202406 -0.156 132.554 -0.159
202409 -0.103 133.029 -0.104
202412 -0.092 133.157 -0.093
202503 -0.096 134.927 -0.096

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


SELLAS Life Sciences Group  (FRA:RXK3) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


SELLAS Life Sciences Group Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of SELLAS Life Sciences Group's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


SELLAS Life Sciences Group Business Description

Traded in Other Exchanges
Address
7 Times Square, Suite 2503, New York, NY, USA, 10036
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

SELLAS Life Sciences Group Headlines

No Headlines